Mark Purcell
Stock Analyst at Morgan Stanley
(1.79)
# 2,081
Out of 4,502 analysts
5
Total ratings
100%
Success rate
23.22%
Average return
Main Sectors:
Top Industries:
5 Stocks
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| NVS Novartis AG | Initiates: Equal-Weight | $114 | $109.93 | +3.70% | 1 | Jan 23, 2024 | |
| SNY Sanofi | Initiates: Equal-Weight | $55 | $53.10 | +3.58% | 1 | Jan 23, 2024 | |
| GSK GSK | Initiates: Equal-Weight | $44 | $39.07 | +12.62% | 1 | Jan 23, 2024 | |
| AZN AstraZeneca | Initiates: Overweight | $85 | $78.52 | +8.25% | 1 | Jan 23, 2024 | |
| NVO Novo Nordisk | Initiates: Overweight | $120 | $127.86 | -6.15% | 1 | Jan 23, 2024 |
Novartis AG
Jan 23, 2024
Initiates: Equal-Weight
Price Target: $114
Current: $109.93
Upside: +3.70%
Sanofi
Jan 23, 2024
Initiates: Equal-Weight
Price Target: $55
Current: $53.10
Upside: +3.58%
GSK
Jan 23, 2024
Initiates: Equal-Weight
Price Target: $44
Current: $39.07
Upside: +12.62%
AstraZeneca
Jan 23, 2024
Initiates: Overweight
Price Target: $85
Current: $78.52
Upside: +8.25%
Novo Nordisk
Jan 23, 2024
Initiates: Overweight
Price Target: $120
Current: $127.86
Upside: -6.15%